In the article “R1626 Plus Peginterferon Alfa-2a Provides Potent Suppression of Hepatitis C Virus RNA and Significant Antiviral Synergy in Combination with Ribavirin” (HEPATOLOGY 2008;48:385-397; DOI: 10.1002/hep.22357), a number of the study investigators were not listed in the acknowledgment section. These investigators are listed below:

  • David E. Bernstein, North Shore–Long Island Health System, Department of Gastroenterology.

  • Natalie Bzowej, California Pacific Medical Center, San Francisco, CA.

  • Stuart C. Gordon, Henry Ford Health System, Detroit, MI.

  • Tarek Hassanein, University of California San Diego Medical Center, San Diego, CA.

  • Donald Jensen, University of Chicago, Chicago, IL.

  • Paul Martin, Mount Sinai School of Medicine, New York, NY.

  • Timothy R. Morgan, VA Long Beach Healthcare System, Long Beach, CA.

  • Lorenzo Rossaro, University of California, Davis Medical Center.